KPTI · XBRL financial data

Karyopharm Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KPTI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue from contracts with customers	108	210	157	146	145	146
Research and development	151	161	149	139	143	126
Selling, general and administrative	126	144	145	132	115	105
Total operating expenses	280	308	299	276	265	237
Operating income (loss)	(172)	(98)	(142)	(130)	(119)	(91)
Interest income	3	1	2	11	7	3
Interest expense	27	26	25	24	37	46
Other income (expense)	0	(0)	(0)	(0)	28	0
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(196)	(124)	(165)	(143)	(76)	(196)
Earnings per share, basic USD per share	(2.72)	(1.65)	(2.02)	(1.25)	(0.63)	(17.93)
Earnings per share, diluted USD per share	(2.72)	(1.65)	(2.02)	(1.25)	(0.93)	(17.93)
Weighted average shares, basic millions of shares	72	75	82	114	0	0
Weighted average shares, diluted millions of shares	72	75	82	114	0	0

† Share count changed about 1/7 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KPTI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	86	190	135	52	62	61
Marketable securities	163	38	143	139	46	3
Marketable securities, non-current	24	—	—	—	—	—
Inventory	3	4	4	3	5	4
Prepaid and other current assets	9	14	20	12	12	9
Total current assets	277	276	350	234	156	103
Property and equipment, net	2	2	1	1	0	0
Right-of-use asset	9	8	6	4	6	5
Total assets	313	305	358	240	164	108
Accounts payable	4	2	3	3	5	4
Accrued liabilities	53	69	58	61	61	64
Total current liabilities	60	74	66	69	92	92
Lease liability, non-current	11	9	6	3	7	6
Total liabilities	263	385	375	377	350	401
Accumulated deficit	(1,070)	(1,179)	(1,344)	(1,487)	(1,563)	(1,759)
Total stockholders' equity	51	(80)	(17)	(136)	(186)	(293)
Total liabilities and equity	313	305	358	240	164	108
Common shares outstanding (cover page) millions of shares	75	79	113	115	126	18

† Share count changed about 1/7 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KPTI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(196)	(124)	(165)	(143)	(76)	(196)
Stock-based compensation	24	30	35	22	18	14
Net cash from operating activities	(160)	(107)	(150)	(93)	(127)	(75)
Purchases of property and equipment	0	0	0	0	0	0
Net cash from investing activities	(54)	142	(104)	8	95	43
Net cash from financing activities	172	74	194	1	42	30
Net change in cash	(42)	108	(61)	(84)	10	(2)

† Share count changed about 1/7 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Karyopharm Therapeutics	55	33	(25)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	0	not reported	(0.2)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
BriaCell Therapeutics	9.9	not reported	(6)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Annovis Bio	19	0*	(22)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3.2	0.6	(3.3)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	14	not reported	(3.2)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
CervoMed	22	0	(6.9)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66	not reported	(7.4)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Actuate Therapeutics	4.4	not reported	(4.4)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.